Bolt Biotherapeutics Files Q1 2025 10-Q
Ticker: BOLT · Form: 10-Q · Filed: May 12, 2025 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, reporting
TL;DR
**Bolt Bio files Q1 10-Q. Financials and ops update.**
AI Summary
Bolt Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key financial data and operational updates are detailed within the filing, which was submitted on May 12, 2025.
Why It Matters
This filing provides investors with an update on Bolt Biotherapeutics' financial health and operational progress during the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Bolt Biotherapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250512 (date) — Filing date
- 900 CHESAPEAKE DRIVE, REDWOOD CITY, CA 94063 (address) — Company business and mailing address
- GenmabAgreement (agreement) — Mentioned in relation to common stock
FAQ
What was Bolt Biotherapeutics' financial performance in the first quarter of 2025?
The 10-Q filing for the period ending March 31, 2025, provides detailed financial statements and performance metrics for Bolt Biotherapeutics during Q1 2025.
What is the company's primary business focus as indicated in the filing?
The filing identifies Bolt Biotherapeutics, Inc. under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations, indicating a focus on drug development and manufacturing.
Where is Bolt Biotherapeutics headquartered?
Bolt Biotherapeutics, Inc. is located at 900 Chesapeake Drive, Redwood City, CA 94063.
When was the company formerly known as Bolt Therapeutics, Inc.?
The company's name changed from Bolt Therapeutics, Inc. on May 4, 2015.
Are there any specific agreements mentioned in the filing related to the company's stock?
Yes, the filing mentions the 'GenmabAgreement' in the context of 'CommonStockMember'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Bolt Biotherapeutics, Inc. (BOLT).